Table 2 Clinical characteristics of patients with Mayo Clinic Imaging Class 1C, 1D, or 1E on tolvaptan versus not on tolvaptan at last follow-up (n = 315).
From: Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
Clinical featuresa | Tolvaptan | Not on tolvaptan |
|---|---|---|
Patient number | 96 | 219 |
Male sex | 55 (57.3%) | 102 (46.6%) |
Age, mean ± SD | 46 ± 13 | 43 ± 14 |
eGFR (CKD-EPI, ml/min/1.73 m2), mean ± SD | 61 ± 27 | 82 ± 26* |
CrCl (ml/min), mean ± SD* | 76 ± 33 | 96 ± 6* |
CKD stage | ||
CKD 1/2 | 39 (40.6%) | 173 (79%)* |
CKD 3 | 49 (51%) | 42 (19.2%)* |
CKD 4/5 | 8 (8.3%) | 4 (1.8%)* |
Genetic mutation—no. (%) | ||
PKD1 PT | 43 (44.8%) | 73 (33.3%) |
PKD1 NT | 27 (28.1%) | 56 (25.6%) |
PKD2 | 17 (17.7%) | 55 (25.1%) |
No PKD1 and PKD2 mutation detected | 7 (7.3%) | 30 (13.7%) |
Not available | 2 (2.1%) | 5 (2.3%) |
ht-TKV, median (IQR)* | 1329 (949–1772) | 848 (609–1298) * |
Mayo Clinic Imaging Class* | ||
1C | 30 (31.2%) | 138 (63%)* |
1D/1E | 66 (68.8%) | 81 (37%)* |
